Moul, J.

cancer patient prostate prostate cancer degarelix level leuprolide baseline treatment study trial disease group degarelix 240/80 mg therapy screening metastatic antigen urology survival psa level s-alp oncology 240/80 hormone metastatic disease testosterone recurrence panel baseline psa levels member psa levels european month university analysis prostate-speci fic antigen stage s-alp levels chemotherapy progression metastatic prostate cancer psa recurrence association oncology /hematology 68 hormone therapy signi result control prostatectomy testing baseline disease stage baseline psa mortality suppression antiandrogen serum prostate-speci population randomized agonist hospital 7.5 american death leuprolide 7.5 mg radiotherapy psa testing oncol difference extension ≥50 ng /ml baseline psa measurements society testosterone surge metastase review marker speci journal